Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DON71B
|
|||
| Drug Name |
Imlunestrant
|
|||
| Synonyms |
Imlunestrant; UNII-9CXQ3PF69U; Imlunestrant [USAN]; LY3484356; 9CXQ3PF69U; 2408840-26-4; LY-3484356; WHO 12039; (5R)-5-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenyl)-8-(trifluoromethyl)-5H-(1)benzopyrano(4,3-c)quinolin-2-ol; 5H-(1)Benzopyrano(4,3-c)quinolin-2-ol, 5-(4-(2-(3-(fluoromethyl)-1-azetidinyl)ethoxy)phenyl)-8-(trifluoromethyl)-, (5R)-; IMLUNESTRANT [INN]; CHEMBL5095183; SCHEMBL22002569; GTPL12896; UVBQMXOKKDCBJN-MUUNZHRXSA-N; BDBM443429; GLXC-26209; US10654866, Example 1A; EX-A6123; Ly 3484356; Example 1B {WO2020014435A1]; HY-145572; CS-0376104; (5R)-5-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-8-(trifluoromethyl)-5H-chromeno[4,3-c]quinolin-2-ol
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65; ICD-10: C50, C79.51] | Phase 3 | [1] | |
| Company |
Lilly
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H24F4N2O3
|
|||
| Canonical SMILES |
C1C(CN1CCOC2=CC=C(C=C2)C3C4=C5C=CC(=CC5=NC=C4C6=C(O3)C=C(C=C6)C(F)(F)F)O)CF
|
|||
| InChI |
InChI=1S/C29H24F4N2O3/c30-13-17-15-35(16-17)9-10-37-21-5-1-18(2-6-21)28-27-23-8-4-20(36)12-25(23)34-14-24(27)22-7-3-19(29(31,32)33)11-26(22)38-28/h1-8,11-12,14,17,28,36H,9-10,13,15-16H2/t28-/m1/s1
|
|||
| InChIKey |
UVBQMXOKKDCBJN-MUUNZHRXSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04975308) EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.